Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group

Final Appraisal Recommendation

Advice No: 0821 – May 2021

Perampanel (Fycompa®) 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg film-coated tablets, and 0.5 mg/ml oral suspension

Limited submission by Eisai Ltd

Recommendation of AWMSG

Perampanel (Fycompa®) is recommended as an option for restricted use within NHS Wales.

Perampanel (Fycompa®) should be restricted to treatment of patients whose seizures are still uncontrolled with the first adjunctive therapy, within its licensed indication for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients from 4 to < 12 years of age.

Perampanel (Fycompa®) is not recommended for use within NHS Wales outside of this subpopulation.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.
- The WPAS only applies to the tablets.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 4770), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.